card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

The potential of applying Flow Cytometry as an IVD technology for CDx

Home / Insights / The potential of applying Flow Cytometry as an IVD technology for CDx

In this episode, Megan McCausland, Scientific Advisor for Flow Cytometry at IQVIA Laboratories, and Scott Bornheimer, Associate Director of Medical and Scientific Affairs at BD Biosciences, discuss the enormous potential of flow cytometry as a clinical diagnostic tool.  Listen as Megan and Scott talk about:

  • Flow cytometry is widely used in exploratory studies and also has attributes distinct from IHC or molecular methods in identifying useful patient selection biomarkers
  • Flow cytometry can be set up in a standardized manner in clinical settings and harmonized across global sites
  • Pharma is requesting assistance with clinical trial assays with the potential for a CDx path, triggering collaboration between Pharma, CRO, and IVD companies

Megan McCausland also points out what will ultimately lead to the use of flow as a CDx in the future: “I think the drug development landscape really continues to evolve towards more personalized medicine. As this happens, biomarkers and their potential translation into companion diagnostics are playing an ever-increasingly important role. The regulatory bodies are pushing, perhaps even expecting, this co-development of biomarkers and treatments with CDx really becoming vital to regulatory approval and clinical use.”

 

To learn more, visit q2labsolutions.com/flow-cytometry